Gilead's CD47 trials freed of FDA hold—for the most part AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warns AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark Carlyle's acquisition of Abingworth brings $2 billion to fuel life science investments Eyes on the prize: Aurion Biotech raises $120M for 'global transformation in the cornea' Aeglea's search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30% With $300M up for grabs, Engitix helps Takeda dig into extracellular matrix in search of IBD drugs Charles River Labs says North American, EU plants will soon use 100% renewable energy Liver enzyme might hold the secret to new obesity treatments The top 20 pharma companies by 2021 revenue Nationwide drug spending grew 7.7% in 2021, will increase another 4%-6% in 2022 Fitbit tails Apple Watch with FDA-cleared algorithm to passively check for afib Wherefore Tavneos? ChemoCentryx and the Brand Institute explain how the #FierceMadness winner got its name Featured Story | By Max Bayer Gilead's CD47 cancer program is back on track—for the most part—after the FDA lifted clinical holds placed in January on five trials. But the agency is keeping two additional trials on ice, Gilead said Monday after market. read more |
| |
|---|
|
Top Stories By Annalee Armstrong,Angus Liu Finding a way to drug KRAS-mutated cancers was a major leap forward for oncology, and we have Amgen to thank for getting the first therapy across the finish line. But Novartis, for one, sees room for improvement. read more By Gabrielle Masson Despite the growing threat posed by drug-resistant bacteria, new antibiotics may not reach the market for another decade, according to the head of a $1 billion fund tasked with seeking out solutions. read more By Annalee Armstrong Myelofibrosis is the cancer that keeps going and going—and AbbVie hopes new data from the phase 2 med navitoclax can make the case for stopping the rare and difficult-to-treat disease in its tracks. read more By Max Bayer Carlyle Group is making its move into funding drug developers with mid-to-late-stage assets, absorbing transnational investment firm Abingworth. The two are also forming a new operating company to oversee, and hopefully better assist, the biopharmas they invest in. read more By Gabrielle Masson Aurion Biotech is setting its sights high with a mission to restore vision for millions of patients via regenerative therapies and a $120 million financing round to back the tech. read more By Nick Paul Taylor Aeglea BioTherapeutics’ bid to rehabilitate the battered reputation of its rare disease drug pegzilarginase has made early progress. Investors responded favorably to the presentation of additional phase 3 data, sending the stock up 21% in light of evidence the enzyme may act on clinical outcomes. read more By Nick Paul Taylor Takeda has tapped Engitix for a solution to an unmet need in inflammatory bowel disease (IBD). Having inked a $500 million deal to work with Engitix in liver diseases in 2020, Takeda has now put up a further $300 million to expand use of the extracellular matrix discovery platform to IBD. read more By Gareth Macdonald Charles River Laboratories says all its facilities in North America and Europe will run on “100% renewable” electricity starting next year. read more By Sophia Sorensen Scientists may have just made a breakthrough in treating the obesity epidemic, and the secret, it turns out, is in your liver. Researchers from The University of Texas Health Science Center at San Antonio found they could decrease appetite and increase fat shedding in obese mice after inhibiting a liver enzyme, with weight loss as the overall result. read more By Kevin Dunleavy 2021 was all about recovery from the COVID-19 pandemic. Several companies that quickly developed products to combat the coronavirus reaped huge profits, while others benefited simply from a return to more normalized business operations. Here's how the year shook out for the top 20 drugmakers by global revenues. read more By Dave Muoio Nonfederal hospitals saw an 8.4% increase in drug spending during 2021 while clinics shouldered a 7.7% gain, according to a recent report from the American Society of Health-System Pharmacists. read more By Andrea Park Fitbit's PPG technology is designed to work in the background throughout the day and night when a wearer is still or asleep. read more By Ben Adams For more than three weeks, 68 drug names battled to become your FierceMadness champion, and in the end, that honor went to ChemoCentryx and its autoimmune disease drug Tavneos. Here's how the company and the Brand Institute came up with the name. read more Resources Sponsored by: Nethealth Net Health, experts in wound care and dermatology clinical trials, have a new eBook: 5 Rules to Enhance Clinical Trials in 2022, find out how to recruit the right participants, connect patients and researchers with technology, manage costs and more. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Cancer Progress 2022: Hear from Leading Oncology Innovators May 10-12, 2022 | Virtual Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Live & Recorded on: Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 